BioNTech SE
22UA
Ранг среди акций
#1009
BioNTech SE is a biotechnology firm dedicated to the research, development, and... BioNTech SE is a biotechnology firm dedicated to the research, development, and marketing of immunotherapies for oncology and a spectrum of infectious diseases. Its diverse product pipeline features several FixVac candidates, including BNT111, currently undergoing Phase II clinical trials for advanced melanoma; BNT112, in Phase I/IIa development for prostate cancer; BNT113, progressing through Phase II for HPV-positive head and neck cancers; BNT114, in Phase I for triple-negative breast cancer; BNT115, also in Phase I for ovarian cancer; and BNT116, a preclinical asset targeting non-small cell lung cancer. Further expanding its oncology focus, BioNTech is advancing neoantigen-specific immunotherapies like Autogene cevumeran (BNT122), which is in Phase II trials for first-line melanoma and Phase 1a/1b trials for multiple solid tumors. The company's mRNA intratumoral immunotherapy, SAR441000, is undergoing Phase I evaluation for solid tumors, complemented by additional neoantigen-specific programs BNT141 and BNT142, both in Phase I clinical studies for various solid malignancies. The firm's portfolio also encompasses RiboCytokines, such as BNT151, BNT152, and BNT153, designed to treat solid tumors. Chimeric antigen receptor T cell (CAR T) immunotherapies include BNT211, aimed at multiple solid tumors, and BNT221 for other cancer types. Additionally, checkpoint immunomodulators GEN1046 and GEN1042 are in Phase I/II clinical development for solid tumor indications. Beyond these, BioNTech is developing BNT321, an IgG1 monoclonal antibody in Phase II trials for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. The company is also actively involved in the creation of prophylactic vaccines for COVID-19 and Influenza, alongside other infectious disease immunotherapies and therapies for rare diseases involving protein replacement. BioNTech maintains strategic alliances with several prominent pharmaceutical and biotechnology entities, including Genentech, Inc., Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE's corporate headquarters are located in Mainz, Germany.
Цена акции
$93.35
Рыночная капитализация
$23.45B
Изменение (1 день)
0.77%
Изменение (1 год)
-10.75%
Страна
DE
Торговля BioNTech SE (22UA)
Категория
Healthcare
Операционная маржа для BioNTech SE (22UA)
Операционная маржа на October 2026 TTM: -64.63%
Согласно последним финансовым отчетам и цене акций BioNTech SE, текущая операционная маржа (TTM) составляет -64.63%. В конце 2023 она составила 18.08%.
История операционной маржи BioNTech SE с 2016 по 2026
Операционная маржа на конец каждого года
| Год | Операционная маржа | Изменить |
|---|---|---|
| 2026 (TTM) | -64.63% | 35.29% |
| 2024 | -47.77% | -364.21% |
| 2023 | 18.08% | -75.24% |
| 2022 | 73.03% | -9.32% |
| 2021 | 80.54% | -571.27% |
| 2020 | -17.09% | -89.78% |
| 2019 | -167.16% | 296.02% |
| 2018 | -42.21% | -57.57% |
| 2017 | -99.48% | 0.00% |
| 2016 | 0.00% | 0.00% |
Операционная маржа для аналогичных компаний или конкурентов
| Компания | Операционная маржа | Разница в операционной марже | Страна |
|---|---|---|---|
| 38.59% | -100.60% |
US
|
|
| -149.01% | -97.69% |
US
|
|
| 25.57% | -100.40% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.45% |
NL
|
Что такое операционная маржа компании?
Операционная маржа — это ключевой показатель прибыльности компании. Более высокая операционная маржа обычно означает, что компания может продавать свои товары или услуги значительно дороже их себестоимости. Она рассчитывается путем деления прибыли компании на её выручку.